Personalised atrial fibrillation management needed to close mortality gap

113

The Atrial Fibrillation competence Network (AFNET) and European Heart Rhythm Association (EHRA) consensus paper is published online in the European Journal of Pacing, Arrhythmias, and Cardiac Electrophysiology (EP-Europace) and was presented during the ESC Congress session on personalised cardiology.

Paulus Kirchhof, UK, said: “Acute and one-year mortality after myocardial infarction has dropped by two-thirds in the last 10 to 15 years primarily because of medical interventions aimed at the principal pathophysiology causing the disease. For example acute revascularisation procedures are used to treat a thrombotic blockage of the artery while statins prevent the development and rupture of coronary plaques.”

He added: “We are in an intermediate position with atrial fibrillation. With the introduction of oral anticoagulant therapy we can prevent about two-thirds of all strokes in atrial fibrillation. But patients with atrial fibrillation still have a higher mortality compared to their age and cardiovascular risk matched peers without atrial fibrillation, and we are not able to reduce that mortality by much even when we apply all the evidence based therapies.”

The fourth AFNET/EHRA consensus conference was convened to discuss how to identify the underlying main pathophysiologies of atrial fibrillation in individual patients so that more targeted therapies could be developed to close the mortality gap. Kirchhof said: “This requires understanding the disease mechanisms and translating them into parameters we can measure in patients. This is particularly difficult for atrial fibrillation because the left atrium is a small part of the heart located posteriorly in the body and difficult to access.”

A certain degree of personalisation is already practised in atrial fibrillation. Stroke risk scores based on clinically measurable risk factors aid decisions on anticoagulant therapy while the severity of atrial fibrillation symptoms help to determine rhythm control therapy, it was stated in a press release.


The consensus paper identifies three main ways to better characterise the underlying cause of atrial fibrillation in order to improve treatment: the electrocardiogram (ECG); imaging, especially echocardiography and magnetic resonance imaging (MRI); and biomarkers (proteins or genes measured in blood to identify the type of atrial fibrillation).

A new taxonomy of atrial fibrillation is proposed based on its pathophysiology. Kirchhof noted: “The classification is imperfect because there are overlaps between categories and the majority of atrial fibrillation patients fall into the “unclassified atrial fibrillation” group. But it illustrates that we need a better understanding of why it develops in an individual patient before we can classify them based on biomarkers, imaging or ECG, in addition to clinical parameters, and develop better therapies.”

He added: “The hope is that within the next few years we will be able to propose personalised management of atrial fibrillation and thereby reduce the excess mortality associated with the disease.”

Kirchhof continued: “There is still plenty of room to improve the management of atrial fibrillation even if we apply all the evidence based therapies currently available-for example the new oral anticoagulants have improved mortality by just 5–10%. And every fourth patient with atrial fibrillation is admitted to hospital at least once a year due to atrial fibrillation, which illustrates the high morbidity and healthcare costs associated with the disease.”

He concluded: “This is the first European consensus document on personalised management of atrial fibrillation, which is the most promising way to further improve morbidity and mortality in atrial fibrillation patients.”